论文部分内容阅读
目的 探讨mdm2癌基因蛋白在骨巨细胞瘤 (GCT)的表达及其与复发的关系。方法 应用SP免疫组织化学方法检测mdm2在 52例GCT中的表达 ;GCT按Jaffe分级 :Ⅰ级 15例 ,Ⅱ级 2 5例 ,Ⅲ级 12例。结果 18例mdm2表达呈阳性 ,占 34 .6% ;在Ⅰ级、Ⅱ级、Ⅲ级中的阳性表达率分别为 4 0 .0 %、32 .0 %、33.3% ;mdm2阳性表达率在骨巨细胞瘤Ⅰ级、Ⅱ级、Ⅲ级中的差异无显著性意义 ( χ2 =0 .2 8,P >0 .0 5)。在 2年随访期内出现复发的 8例中 ,有 6例阳性表达 ,无复发的 4 4例中有 12例阳性表达 ,两者差异显著 ( χ2 =6.81,P <0 .0 1)。结论 mdm2在GCT中的表达与病理分级无关 ,但与其复发有关
Objective To investigate the expression of mdm2 oncogene protein in giant cell tumor of bone (GCT) and its relationship with recurrence. Methods SP immunohistochemistry was used to detect the expression of mdm2 in 52 cases of GCT. According to Jaffe’s classification, GCT was classified as grade Ⅰ in 15 cases, grade Ⅱ in 25 cases, and grade Ⅲ in 12 cases. Results The positive expression rate of mdm2 in 18 cases was 34.6%. The positive expression rates of grade 1, grade 2 and grade 3 were 40.0%, 32.0% and 33.3% respectively. The positive expression rate of mdm2 in bone There was no significant difference in grade Ⅰ, grade Ⅱ and grade Ⅲ of giant cell tumor (χ2 = 0.28, P> 0.05). Of the 8 patients who relapsed within 2 years of follow-up, 6 were positive, and 12 of the 4 patients without recurrence were positive (χ2 = 6.81, P <0.01). Conclusion The expression of mdm2 in GCT has nothing to do with the pathological grade, but related to its recurrence